Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - SubB2M/CA15.3 Clinical Validation Data Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test (ASX:IIQ)

Highlights INOVIQ’s SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) The results of a comprehen...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - March 2023 (ASX:IIQ)

Progress on EXO-NET® commercialisation with Academia and Industry INOVIQ presented on EXO-NET and exosomes to the Preterm Birth International Collaborative #PREBIC Aus...read more

INOVIQ - Appendix 4D and Half Year Financial Report (ASX:IIQ)

To view the Appendix 4D and Half Year Financial Report, download the attached PDF.

INOVIQ - Positive results for SubB2M Breast Cancer Test (ASX:IIQ)

INOVIQ’s SubB2M-enhanced CA15.3 breast cancer test outperforms a leading commercially available CA15.3 tumour marker test Data from a 94-serum case-control study demonstrates...read more

INOVIQ - Appendix 4C & Quarterly Activities Report - December 2022 (ASX:IIQ)

Highlights -- INOVIQ kicked off EXO-NET sales campaign in the US and reverted to a direct distribution model for hTERT sales in the US -- Contract Research Agreement signed with Nicoya to develo...read more

INOVIQ - Positive EXO-NET Results in Ovarian Cancer (ASX:IIQ)

-- EXO-NET® feasibility study completed by The University of Queensland, confirms the utility of EXO-NET for isolating Extracellular Vesicle (EV) biomarkers and development of an EV-based ovaria...read more

INOVIQ - MST Access Diagnostics Forum Presentation (ASX:IIQ)

Melbourne, Australia, 5 December 2022: INOVIQLimited (ASX:IIQ) (INOVIQ or the Company) advises that CEO Dr Leearne Hinch will deliver the attached presentation to investors and shareholders at&...read more

INOVIQ - CEO AGM Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Settles Legal Proceedings (ASX:IIQ)

INOVIQ has settled the legal proceeding related to the BARD1 performance shares Plaintiffs to receive BARD1 Lung Cancer Test IP and $1 million payment. INOVIQ retains Breast&nb...read more

INOVIQ - Commercial and R&D Update (ASX:IIQ)

Key points: -- US commercial roll out of EXO-NET® delivering strong customer interest following implementation of sales campaign by contract sales team -- US distribution of the hTERT ICC te...read more

INOVIQ - Healthcare Conference Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Appendix 4C & Quarterly Activities Report-September 2022 (ASX:IIQ)

SubB2M-based Surface Plasmon Resonance (SPR) test to be developed with Nicoya on the Alto™ Digital SPR instrument Contract sales force appointed via agreement with P...read more

INOVIQ - Canadian Patent Granted for BARD1 Technology (ASX:IIQ)

Key points: -- Canadian Patent No. 2,929,457 granted covering lung cancer diagnosis -- IP protection in Canada for BARD1 autoantibody test for diagnosis of lung cancer in Canada Melbourne, Au...read more

INOVIQ - Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Viewing: 31 - 45 of 111 Previous | Next